Tuberculosis (TB) continues to be a formidable global health challenge, demanding urgent innovation in treatment and diagnosis. The efficacy of current anti-TB drugs is often compromised by issues such as short drug half-life, rapid drug degradation, low drug concentration at the site of infection, and significant off-target effects.
